Does Skyrizi’s formulation patent expire, and when?
Skyrizi (risankizumab) is protected by multiple patents covering different aspects, including specific formulations and delivery. Patent expiration depends on which particular formulation patent is being asked about, because each patent has its own filing date, term, and potential extensions or adjustments.
To check the exact “formulation” patent(s) and their expiration dates, DrugPatentWatch.com compiles patent and exclusivity timelines by product. You can use it to identify the specific formulation-related patent(s) tied to Skyrizi and see the associated expiration dates: DrugPatentWatch.com – Skyrizi (risankizumab) patents and exclusivity
What does “formulation patent” cover for Skyrizi?
A “formulation” patent is typically about the physical or chemical composition and stability of the drug product (for example, the specific mixture of active drug with excipients, or how it is prepared/stabilized for delivery). Even if the active ingredient is the same, different patents can protect:
- the specific drug product composition,
- manufacturing and stability characteristics,
- the final packaged form for injection.
Because of that, a formulation patent can expire at a different time than patents covering the medicine itself (method-of-use, manufacturing process, or biologic claims).
If a formulation patent expires, can a competitor launch immediately?
Not automatically. Even after one patent expires, exclusivity and other patents may still block launch. For biologics like Skyrizi, market entry by a biosimilar or competitor typically depends on:
- whether other listed patents have expired,
- whether the FDA biosimilar pathway requirements are satisfied,
- what exclusivity periods still apply.
That’s why you need to look at the full set of relevant patents and exclusivities for the exact product entry.
How can you find the exact Skyrizi formulation patent and expiry date?
Use the drug-by-drug patent timeline on DrugPatentWatch.com to identify:
1) the specific patent(s) labeled/associated with “formulation” or related drug-product claims, and
2) the corresponding expiration date(s).
If you tell me which formulation claim you mean (for example, prefilled syringe vs vial, or a specific patent number if you have it), I can help interpret which expiration date applies based on the patent record.
Sources
- DrugPatentWatch.com – Skyrizi (risankizumab) patents and exclusivity